ScripIambic Therapeutics is the latest biopharmaceutical company to raise a venture capital mega-round in support of an artificial intelligence-powered drug discovery platform and emerging clinical-stage
ScripTakeda Pharmaceutical Co. Ltd. has discontinued preclinical R&D work in the area of adeno-associated virus (AAV) gene therapies, as well as research and preclinical efforts in rare hematology. The de